

CITATION REPORT

List of articles citing

Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor

DOI: 10.1016/0192-0561(94)90054-x

**International Journal of Immunopharmacology, 1994,
16, 805-16.**

Source: <https://exaly.com/paper-pdf/25089576/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
109	Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Inhibitors of TNF α synthesis. 1995 , 5, 1087-1100		14
108	Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors. 1995 , 44, 400-5		32
107	The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A. 1995 , 44, 269-74		30
106	Inhibition of LPS-induced TNF alpha production in human monocytes by adenosine (A2) receptor selective agonists. <i>International Journal of Immunopharmacology</i> , 1995 , 17, 221-4		41
105	The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide. <i>International Journal of Immunopharmacology</i> , 1995 , 17, 605-10		29
104	Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a low-affinity phosphodiesterase 4 conformer. 1996 , 118, 649-58		95
103	Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis. 1996 , 299, 229-33		13
102	Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. 1996 , 51, 949-56		92
101	Phosphodiesterase 4 inhibitors and db-cAMP inhibit TNF-alpha release from human mononuclear cells. Effects of cAMP and cGMP-dependent protein kinase inhibitors. 1996 , 5, 425-8		7
100	Phosphodiesterase type IV inhibitors. 1996 , 33, 1-52		38
99	Evaluation of human cytokine production and effects of pharmacological agents in a heterologous system in vivo. 1996 , 195, 1-5		11
98	The inhibitory effect of pentamidine on the production of chemotactic cytokines by in vitro stimulated human blood cells. 1996 , 45, 357-63		10
97	Nitric oxide increases tumor necrosis factor production in differentiated U937 cells by decreasing cyclic AMP. 1997 , 272, 5959-65		54
96	Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor. 1997 , 332, 97-107		16
95	The effect of rolipram on the production of cytokines in HTLV-I infected cell lines and peripheral blood mononuclear cells of patients with HTLV-I-associated myelopathy (HAM). 1997 , 148, 87-94		5
94	Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. 1997 , 79, 54-61		67
93	Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?. 1997 , 18, 164-71		150

92	Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?. 1997 , 18, 164-170	163
91	In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. 1997 , 121, 221-31	114
90	Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a low-affinity phosphodiesterase 4 conformer. 1997 , 121, 743-50	24
89	Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. 1997 , 122, 149-57	79
88	Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway. 1997 , 52, 917-25	93
87	Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. 1997 , 9, 227-36	160
86	Biarylcarboxamide inhibitors of phosphodiesterase IV and tumor necrosis factor- α . 1997 , 7, 739-744	8
85	Selective type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells. 1997 , 27, 816-823	11
84	Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. 1998 , 123, 1031-8	63
83	Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes. 1998 , 29, 179-201	47
82	Pharmacological modulation of cytokine action and production through signaling pathways. 1998 , 9, 239-57	27
81	Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. 1998 , 157, 351-70	595
80	1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. 1998 , 41, 821-35	126
79	The role of phosphodiesterase enzymes in allergy and asthma. 1998 , 44, 33-89	35
78	Phosphodiesterases 4 Inhibitors. 1998 , 91-109	16
77	Effects of phosphodiesterase inhibitors on secretions of human monokines. 1998 , 47, 219-224	2
76	Pharmacological modulation of LPS-induced MIP-1 alpha production by peripheral blood mononuclear cells. 1998 , 56, 230-6	13
75	Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. 1998 , 275, E757-62	20

74	Cytotoxic effects of NSL-1406, a new thienopyrimidine derivative, on leukocytes and osteoclasts. 1999 , 9, 797-802	28
73	Effects of mitogen-activated protein kinase inhibitors or phosphodiesterase inhibitors on interleukin-1-induced cytokines production in synovium-derived cells. 1999 , 68, 275-9	22
72	Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats. <i>International Journal of Immunopharmacology</i> , 1999 , 21, 711-25	18
71	Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. 1999 , 57, 965-73	110
70	Does tumor necrosis factor-alpha (TNF-alpha) contribute to myocardial reperfusion injury in anesthetized rats?. 1999 , 32, 41-5	7
69	Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. 2000 , 84, 58-66	17
68	Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo. 2000 , 27, 787-92	8
67	Monoamine oxidase inhibitors in rheumatoid arthritis-anti-tumor necrosis factor?. <i>International Journal of Immunopharmacology</i> , 2000 , 22, 1007-8	6
66	Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. 2000 , 47, 127-62	216
65	Synthesis and structure-activity relationships of novel compounds for the inhibition of TNF-alpha production. 2000 , 23, 332-7	6
64	Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7, 1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors. 2000 , 43, 4850-67	38
63	Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. 2000 , 27, 811-7	82
62	Phosphodiesterase type 4 inhibitors: potential in the treatment of multiple sclerosis?. 2000 , 13, 87-94	15
61	Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?. 2000 , 59, 193-212	127
60	Remission of Crohn's disease on bupropion. 2001 , 121, 1260-1	46
59	Cyclic nucleotide phosphodiesterases. 2001 , 108, 671-80	328
58	Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. 2001 , 14, 157-64	49
57	Monoamine oxidase inhibitors for IgA nephropathy. 2001 , 56, 225-6	3

56	Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors. 2001 , 417, 11-8	11
55	Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. 2002 , 99, 7628-33	294
54	Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors. 2002 , 63, 1527-35	24
53	Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats. 2003 , 465, 133-9	11
52	Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors. 2003 , 13, 2347-50	3
51	Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. 2003 , 15, 827-35	65
50	Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. 2004 , 68, 2229-36	33
49	Selective Phosphodiesterase Inhibitors in the Treatment of Respiratory Disease. 2004 , 179-218	
48	The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. 2004 , 5, 4	20
47	Caffeine suppresses TNF-alpha production via activation of the cyclic AMP/protein kinase A pathway. 2004 , 4, 1409-17	80
46	PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. 2005 , 106, 269-97	88
45	Clinical pharmacology of Cilomilast. 2006 , 45, 217-33	6
44	Impairment of TNF-alpha production and action by imidazo[1,2- alpha] quinoxalines, a derivative family which displays potential anti-inflammatory properties. 2006 , 19, 525-38	10
43	The antidepressant and antiinflammatory effects of rolipram in the central nervous system. 2001 , 7, 387-98	137
42	Nimesulide-induced antipyresis in rats involves both cyclooxygenase-dependent and independent mechanisms. 2006 , 543, 181-9	5
41	Modulation of the cAMP signaling pathway after traumatic brain injury. 2007 , 208, 145-58	113
40	Effects and mechanisms of total glucosides of paeony on adjuvant arthritis in rats. 2007 , 109, 442-8	76
39	Effects and mechanisms of catechin for adjuvant arthritis in rats. 2007 , 24, 679-90	24

38	The efficacy and safety of cilomilast in COPD. 2008 , 68 Suppl 2, 3-57	36
37	Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock. 2008 , 12, R159	15
36	Effects and mechanisms of total glucosides of paeony on synoviocytes activities in rat collagen-induced arthritis. 2009 , 121, 43-8	71
35	Phosphodiesterase inhibitors in the management of autoimmune disease. 2010 , 9, 511-5	24
34	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. 2010 , 10, 26	29
33	Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways. 2010 , 24, 73-82	2
32	βAdrenoceptor activation depresses brain inflammation and is neuroprotective in lipopolysaccharide-induced sensitization to oxygen-glucose deprivation in organotypic hippocampal slices. 2010 , 7, 94	34
31	Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. 2010 , 12, R107	93
30	Paeoniflorin inhibits function of synoviocytes pretreated by rIL-1β and regulates EP4 receptor expression. 2011 , 137, 1275-82	36
29	Low-level laser therapy (LLLT) acts as cAMP-elevating agent in acute respiratory distress syndrome. 2011 , 26, 389-400	33
28	Potential for phosphodiesterase inhibitors in the management of autoimmune diseases. 2011 , 72, 772-778	1
27	Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells. 2012 , 25, 178-84	23
26	Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury. 2012 , 90, 1861-71	14
25	Small-molecule inhibitors of the interaction between TNF and TNFR. 2013 , 5, 69-79	26
24	The prostanoid EP4 receptor and its signaling pathway. 2013 , 65, 1010-52	174
23	GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. 2013 , 14, 727-34	52
22	Inhibition of Phosphodiesterases as A Strategy for Treatment of Spinal Cord Injury. 2014 , 353-374	
21	Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. 2015 , 194, 101-12	11

20	Cardiac Fibroblast GRK2 Deletion Enhances Contractility and Remodeling Following Ischemia/Reperfusion Injury. 2016 , 119, 1116-1127		59
19	PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. 2016 , 16 Suppl, S67-73		3
18	Precision Medicine in Rheumatoid Arthritis. 2017 , 43, 377-387		25
17	Treatment of endotoxaemia and septicaemia in the equine patient. 2017 , 40, 1-15		12
16	Potent immunosuppressive activity of a phosphodiesterase-4 inhibitor N-acylhydrazone in models of lipopolysaccharide-induced shock and delayed-type hypersensitivity reaction. 2018 , 65, 108-118		2
15	Pyrrolo[2,3]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and / assessment. 2021 , 1230, 129868		17
14	Regulation of cytokine production by inhibitors of cell signalling. 2000 , 43-82		1
13	Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). 1999 , 53, 193-229		76
12	Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32, 769-76	3.1	11
11	The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge. 2013 , 8, e61193		3
10	Phosphodiesterase inhibitors as therapeutics for traumatic brain injury. 2015 , 21, 332-42		19
9	Phosphodiesterase 4B: Master Regulator of Brain Signaling. <i>Cells</i> , 2020 , 9,	7.9	11
8	Phosphodiesterase inhibitors for respiratory diseases. 2000 , 223-253		
7	Insights into the Physiological Functions of PDE4 from Knockout Mice. 2006 ,		
6	Effect of the type IV phosphodiesterase inhibitor Ro 20-1724 on catecholamine-induced alterations in regional vascular resistance and regional blood flow. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 31, 840-53	3.1	
5	A Sonochemical Access to 5-Aryl Substituted Pyrazolo[1,5-a]Pyrimidines as Potential Inhibitors of TNF- α <i>Polycyclic Aromatic Compounds</i> , 1-18	1.3	0
4	Mitochondrial Photobiomodulation as a Neurotherapeutic Strategy for Epilepsy. <i>Frontiers in Neurology</i> , 13,	4.1	2
3	In silico studies, sonochemical synthesis and biological evaluation of 4-substituted pyrimido[1,2-b]indazoles. 2022 , 134273		0

- 2 Ultrasound Assisted Arylation of Ketones: A Rapid Access to Isoquinolinone Derivatives. **2022**, 7, 60
- 1 Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF- α **1999**, 163, 380-386 60